<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02808572</url>
  </required_header>
  <id_info>
    <org_study_id>UF9125</org_study_id>
    <nct_id>NCT02808572</nct_id>
  </id_info>
  <brief_title>New Biomarkers of Bone Mineral Metabolism as Cardiovascular Risk Factors in Chronic Kidney Disease Patients</brief_title>
  <official_title>New Biomarkers of Bone and Mineral Metabolism as Risk Factors for Morbidity/Mortality in Chronic Kidney Disease Patients Not Requiring Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the relationships between bone mineral metabolism markers (osteoprotegerin,
      fibroblast growth factor 23) at inclusion and the occurence of cardiovascular events during a
      7 year follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2013</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurence of at least one cardiovascular event during the 7 year follow-up according to osteoprotegerin level at inclusion</measure>
    <time_frame>7 years after inclusion</time_frame>
    <description>osteoprotegerin will be measured in picomol/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurence of at least one cardiovascular event during the 7 year follow-up according to fibroblast growth factor 23 level at inclusion</measure>
    <time_frame>7 years after inclusion</time_frame>
    <description>fibroblast growth factor 23 will be measured in RU/milliliter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of at least one cardiovascular event during the 7 year follow-up according to vascular calcification score at inclusion</measure>
    <time_frame>7 years after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>7 years after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney functions</measure>
    <time_frame>during the 7 year follow-up</time_frame>
    <description>values of creatinine</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Cardiovascular risk evaluation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Measurement at inclusion of plasma osteoprotegerin level, plasma fibroblast growth factor 23 level, vascular calcification score and record of cardiovascular events during the 3 year follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Plasma osteoprotegerin level</intervention_name>
    <description>dosage of plasma osteoprotegerin</description>
    <arm_group_label>Cardiovascular risk evaluation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Plasma fibroblast growth factor 23 level</intervention_name>
    <description>dosage of plasma fibroblast growth factor 23</description>
    <arm_group_label>Cardiovascular risk evaluation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Vascular calcification score</intervention_name>
    <description>measurement of vascular calcification score by multidetection computerized tomography</description>
    <arm_group_label>Cardiovascular risk evaluation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient who has signed the written consent form

          -  Patient with chronic renal failure defined by glomerular filtration rate (GFR) but
             without dialysis therapy

        Exclusion Criteria:

          -  Pregnancy

          -  Patient with chronic renal failure requiring dialysis therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Paul CRISTOL, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Lapeyronie, Department of Biochemistry and Hormonology, Montpellier, FRANCE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Paul CRISTOL, Prof</last_name>
    <phone>+33(0)4 67 33 83 15</phone>
    <email>jp-cristol@chu-montpellier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marion Morena, PhD</last_name>
    <phone>+33(0)4 11 75 98 93</phone>
    <email>m-morenacarrere@chu-montpellier.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AIDER</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lotfi Chalabi, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Lotfi Chalabi, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier, Cardiology department</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier, Endocrinology department</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Renard, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Eric Renard, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier, Intensive care unit</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier, Internal medicine department</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier, Nephrology department</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène Leray-Moragues, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Hélène Leray-Moragues, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leila Chenine, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 17, 2016</study_first_submitted>
  <study_first_submitted_qc>June 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2016</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic kidney disease</keyword>
  <keyword>vascular calcifications</keyword>
  <keyword>cardiovascular risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

